scholarly journals Methylenetetrahydrofolate Reductase Polymorphisms and Susceptibility to Esophageal Cancer in Chinese Populations: a Meta-analysis

2014 ◽  
Vol 15 (3) ◽  
pp. 1345-1349 ◽  
Author(s):  
Yong-Bin Yang ◽  
Yan-Hong Shang ◽  
Yan-Li Tan ◽  
Xian-Jiang Kang ◽  
Ming Meng ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Methylenetetrahydrofolate Reductase ◽  
Meta Analysis ◽  
Chinese Populations

scholarly journals Association of Chinese sauerkraut consumption with esophageal cancer in Chinese populations: A meta-analysis

2019 ◽  
Author(s):  
Dan Han ◽  
Shuang Liu ◽  
Kaige Liang ◽  
yaojiang huang
Keyword(s):  
Esophageal Cancer ◽  
Random Effects ◽  
Meta Analysis ◽  
Geographic Area ◽  
Positive Outcome ◽  
Chinese Populations ◽  
Search Terms ◽  
Increased Risk ◽  
Publication Language ◽  
Trim And Fill

Abstract Background With accumulating evidence showing that Chinese sauerkraut consumption may be associated with the developmental of Esophageal cancer.Objective We carried out a analysis by R to Evaluate whether the consumption of Chinese sauerkraut is associated with Esophageal cancer in Chinese populations.Methods Two independent investigators carry out a systematic search through Oct 8, 2019 for all studies. The search terms included Chinese sauerkraut, Chinese pickled vegetable, and Suancai, in combination with Esophageal cancer. Investigators extracted, pooled and analysed data from the included studies using a random-effects model in R.Results A random-effects meta-analysis of all 23 studies, including 32,259 unique participants, indicated that Chinese sauerkraut consumption is associated with a significantly increased risk of Esophageal cancer compared to controls (OR=1.81, 95% CI=1.50-2.19, P=0.00001). Sensitivity analysis showed that no single study significantly influenced the overall association. Most of the subgroup analyses, including those of subtype of EC, geographic area, publication language and year, demonstrated a statistically significant association between consuming Chinese sauerkraut and Esophageal cancer risk. Meta-regression indicated that gender and publication year is positively correlated with effect sizes. Furthermore, the trim-and-fill method used to adjust for funnel plot asymmetry in our meta-analysis confirmed that a positive outcome is unlikely to be due to publication bias.Conclusion The results of this meta-analysis provide evidence that consuming Chinese sauerkraut may increase the risk of Esophageal cancer.

scholarly journals Fibroblast Growth Factor 20 Gene Polymorphism in Parkinson’s Disease in Asian Population: A Meta-Analysis

Genes ◽  
2021 ◽  
Vol 12 (5) ◽  
pp. 674
Author(s):  
Han-Lin Chiang ◽  
Yih-Ru Wu ◽  
Yi-Chun Chen ◽  
Hon-Chung Fung ◽  
Chiung-Mei Chen
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Meta Analysis ◽  
Lewy Bodies ◽  
Asian Population ◽  
Protective Role ◽  
Lewy Neurites ◽  
Chinese Populations ◽  
Study Results

Parkinson’s disease (PD) is a neurodegenerative disease with the pathological hallmark of Lewy bodies and Lewy neurites composed of α-synuclein. The SNP rs591323 is one of the risk loci located near the FGF20 gene that has been implicated in PD. The variation of FGF20 in the 3′ untranslated region was shown to increase α-synuclein expression. We examined the association of rs591323 with the risk of PD in a Taiwanese population and conducted a meta-analysis, including our study and two other studies from China, to further confirm the role of this SNP in Taiwanese/Chinese populations. A total of 586 patients with PD and 586 health controls (HCs) were included in our study. We found that the minor allele (A) and the AA + GA genotype under the dominant model are significantly less frequent in PD than in controls. The meta-analysis consisted of 1950 patients with PD and 2073 healthy controls from three studies. There was significant association between rs591323 and the risk of PD in the additive (Z = −3.96; p < 0.0001) and the dominant models (Z = −4.01; p < 0.0001). Our study results and the meta-analysis support the possible protective role of the rs591323 A allele in PD in Taiwanese/Chinese populations.

scholarly journals The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review

2021 ◽  
Vol 28 ◽  
pp. 107327482199743
Author(s):  
Ke Chen ◽  
Xiao Wang ◽  
Liu Yang ◽  
Zheling Chen
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Survival Rate ◽  
Meta Analysis ◽  
Response Rates ◽  
Control Group ◽  
Term Survival ◽  
Long Term Survival ◽  
And Control

Background: Treatment options for advanced gastric esophageal cancer are quite limited. Chemotherapy is unavoidable at certain stages, and research on targeted therapies has mostly failed. The advent of immunotherapy has brought hope for the treatment of advanced gastric esophageal cancer. The aim of the study was to analyze the safety of anti-PD-1/PD-L1 immunotherapy and the long-term survival of patients who were diagnosed as gastric esophageal cancer and received anti-PD-1/PD-L1 immunotherapy. Method: Studies on anti-PD-1/PD-L1 immunotherapy of advanced gastric esophageal cancer published before February 1, 2020 were searched online. The survival (e.g. 6-month overall survival, 12-month overall survival (OS), progression-free survival (PFS), objective response rates (ORR)) and adverse effects of immunotherapy were compared to that of control therapy (physician’s choice of therapy). Results: After screening 185 studies, 4 comparative cohort studies which reported the long-term survival of patients receiving immunotherapy were included. Compared to control group, the 12-month survival (OR = 1.67, 95% CI: 1.31 to 2.12, P < 0.0001) and 18-month survival (OR = 1.98, 95% CI: 1.39 to 2.81, P = 0.0001) were significantly longer in immunotherapy group. The 3-month survival rate (OR = 1.05, 95% CI: 0.36 to 3.06, P = 0.92) and 18-month survival rate (OR = 1.44, 95% CI: 0.98 to 2.12, P = 0.07) were not significantly different between immunotherapy group and control group. The ORR were not significantly different between immunotherapy group and control group (OR = 1.54, 95% CI: 0.65 to 3.66, P = 0.01). Meta-analysis pointed out that in the PD-L1 CPS ≥10 sub group population, the immunotherapy could obviously benefit the patients in tumor response rates (OR = 3.80, 95% CI: 1.89 to 7.61, P = 0.0002). Conclusion: For the treatment of advanced gastric esophageal cancer, the therapeutic efficacy of anti-PD-1/PD-L1 immunotherapy was superior to that of chemotherapy or palliative care.

Sign in / Sign up

Export Citation Format

Share Document